ReviewOncology letters2019
Molecular and cellular stratagem of brain metastases associated with melanoma.
Review in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 54 citations in OpenAlex.
- A Review on Melanoma Brain Metastases.Current pharmaceutical design · 2026Review
- The Neuro-Melanoma Singularity: Convergent Evolution of Neural and Melanocytic Networks in Brain Metastatic Adaptation.Biomolecules · 2025Review
- An Update on the Nutritional and Therapeutic Potential ofFood science & nutrition · 2025Review
- An Update on Antitumor Efficacy of Catechins: From Molecular Mechanisms to Clinical Applications.Food science & nutrition · 2025Review
- Current Evidence on Molecular Mechanisms of Andrographolide in Cancer.Current medicinal chemistry · 2025Review
- Diosmin: A promising phytochemical for functional foods, nutraceuticals and cancer therapy.Food science & nutrition · 2024Review
- Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases.Nutrients · 2023Review
- Natural antioxidants from some fruits, seeds, foods, natural products, and associated health benefits: An update.Food science & nutrition · 2023Review
- An updated overview of anticancer effects of alternariol and its derivatives: underlying molecular mechanisms.Frontiers in pharmacology · 2023Review
- An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer.Frontiers in pharmacology · 2023Review
- Phytates as a natural source for health promotion: A critical evaluation of clinical trials.Frontiers in chemistry · 2023Review
- Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms.Journal of translational medicine · 2022Review
- Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation.Cancer cell international · 2022Review
- Sesquiterpenoid lactones as potential anti-cancer agents: an update on molecular mechanisms and recent studies.Cancer cell international · 2022Review
- Eryngium caeruleum: an update on ethnobotany, phytochemistry and biomedical applications.Chinese medicine · 2022Review
- Recent advances and limitations of mTOR inhibitors in the treatment of cancer.Cancer cell international · 2022Review
- Apoptosis evasion via long non-coding RNAs in colorectal cancer.Cancer cell international · 2022Review
- Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets.Cancer cell international · 2022Review
- Targeting Ras-ERK cascade by bioactive natural products for potential treatment of cancer: an updated overview.Cancer cell international · 2022Review
- Myricetin: targeting signaling networks in cancer and its implication in chemotherapy.Cancer cell international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumors of the central nervous system are the most prevalent complications of melanoma, especially in the late stage of disease. Melanoma, lung and breast cancer are the leading cause of secondary tumors in the brain, the majority of them having a poor outcome. Brain dissemination is developed in half of stage IV melanomas and these cases can increase up to 75%, having a major impact on the quality of life. This review will focus on recent findings that provide new ways to potentially prevent brain metastases in malignant melanoma. The key of these findings is based on the heterogeneity of the melanoma and of the brain metastases at genetic levels. This new era of technologies provides new tools in understanding the dissemination mechanisms of malignant cells. The cellular and molecular changes, the immune status of the patient and the blood-brain barrier permeability are key regulators of cancer cell dissemination. Understanding these mechanisms can render new hope in preventing brain metastases by focusing on melanoma and new pharmacologic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.